Quanterix highlights Akoya acquisition benefits; responds to Kent Lake director nominations

Quanterix Corp

Acquisition unlocks $5B addressable market in spatial biology and $10B Alzheimer's diagnostics opportunity.
Expects ~$40M annual run-rate cost synergies by end of 2026, with $20M in the first year after close.
Targets ~$1B revenue and ~15% EBIT margins within five years post-close; positive free cash flow expected in 2026.
Kent Lake PR LLC nominated three director candidates for 2025 Annual Meeting; Quanterix criticizes assumptions as flawed.
Transaction expected to close in Q2 2025, pending shareholder approvals and customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.